India's Pharmaceutical Industry: The Journey Ahead May 7, 2008

Spurred on by global ambitions of its top players, formidable core competencies and an evolving global marketplace, the Indian pharmaceutical industry is perhaps at inflection point towards a phase of high value growth with increasing international revenues and the emergence of innovative business models. Dr Brian Tempest - former Chief Mentor and Executive Vice Chairman of Ranbaxy Laboratories is particularly well placed to draw on his experiences both at Ranbaxy - one of the world's largest generic pharmaceutical companies and within global pharmaceutical leadership roles over 37 years, to discuss what future leading Indian pharmaceutical companies will look like, and what opportunities this presents for UK R&D.

Professor Barry Furr, former Chief Scientific Officer at Astra Zeneca, well versed with pharmaceutical R&D across the world including notably Astra Zeneca's Tuberculosis Research Center in Bangalore will moderate the discussion raising pertinent questions. This event will be a unique opportunity to learn the views of two experienced industry veterans about a group of companies that could well shake up the global industry.
Dr Brian W Tempest, Chief Mentor & Executive Vice Chairman of the Board, Ranbaxy Laboratories, New Delhi, India

Dr. Brian Tempest has worked in the pharma industry for the last 36 years. During this time he has worked for several pharma majors, including Glaxo & Searle, around the world and joined Ranbaxy 12 years ago. During this period Ranbaxy has transformed from a small company focused on the India domestic market, to a top 10 global generic company. Dr. Tempest lives in New Delhi, India and has been President, Managing Director & Chief Executive Officer and is presently the Chief Mentor & Executive Vice Chairman of the Board. Dr. Tempest retired from Ranbaxy in 2007. Dr. Tempest is one of a few westerners to hold a leadership position in an Indian blue chip MNC, and has a unusual insight into India.Dr Tempest is also an Honorary Professor of the Management School at Lancaster University, UK, and he sits on the Editorial Board of the Journal of Generic Medicines.
Further information

Timing:
* 5.15pm: Registration (please arrive as close to this time as possible)
* 5.30pm: Event starts
* 7.30pm: Event ends

Pricing:
* £15 + VAT (£17.63) to R&D Society Individual and Corporate members
* £40 + VAT (£47.00) for Executives
* £20 + VAT (£23.50) for Asian citizens/institutions, officials, executives from Small Companies
* £10 + VAT (£11.75) for Academics
* Free to Olswang Supporters
* Free for the Media.

To Register

Please send your details (name, institutional affiliation, email address, phone number) to [email protected] Please state at which of the above prices you wish to be invoiced. You can mark yourself as attending here, but please book by email to guarantee a place.

Official Website: http://www.rdsoc.org/08L5.html